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repair than men
Manish Mehta, W. John Byrne, Handel Robinson, Sean P. Roddy, Philip S. K.
Paty, Paul B. Kreienberg, Paul Feustel, R. Clement Darling III
Background: Women have a lower chance of surviving elective open
abdominal aortic repair. The reasons for this are notclear. Endovascular
repair has clearly reduced early and midterm morbidity and mortality for
patients with largeabdominal aortic aneurysms (AAAs). However, most
patients are male. It is unclear whether there has been any reductionin
elective morbidity for females or what the extent of that reduction has
been. We prospectively analyzed outcomes forelective endovascular
aneurysm repair (EVAR) in women at our center and compared results
with those for elective opensurgery and emergent open and endovascular
repair.
Methods: All patients undergoing elective and emergency AAA from 2002
to 2009 were prospectively entered into adatabase. Demographic details,
including gender, were tabulated. Outcome measures were operative
blood loss, incidenceof type 1 endoleaks, length of in-hospital stay, post-
operative complications, 30-day all-cause mortality, and secondar-
yinterventions during the follow-up period. Statistical analysis was
performed using Fischer exact test and Student t test.A multivariate
analysis was also performed.
Results: From 2002 to 2009, there were 2631 abdominal aortic aneurysms
(AAA) open and endovascular repairsperformed in our center (1698
endovascular aneurysm repairs [EVARs], 933 “open”). Males comprised
1995 (76%) of patients; females 636 (24%). There were 1592 elective EVARs
(1248 male, 344 female) and 106 emergency EVARs (73male, 33 female).
Elective open repair was performed in 788 patients (579 male, 209 female)
and emergency open repairin 149 (73 male, 76 female). For women,
elective EVAR resulted in signiﬁcantly greater mortality rates than men
(3.2% vs 0.96%, P < .005). There was a greater incidence of intraoperative
aortic neck or iliac artery rupture (4.1% vs 1.2% P ¼ .002) and use of Palmaz
stents for type 1 endoleaks (16.1% vs 8%, P ¼ .0009). Mean blood loss was
greater in females (327 mL vs 275 mL, P ¼ .038). Perioperative complica-
tions were also more frequent in women: leg ischemia (3.5% vs 0.6%, P ¼
.003) and colon ischemia requiring colectomy (0.9% vs 0.2%, P ¼ .009).
Mean hospital stay was also longer (3.7 days vs 2.2 days, P ¼ .0001). In
contrast, there were no gender differences for any of these outcome
measures for electiveopen repair or emergency open surgery or EVAR.
There was no signiﬁcant difference in death rates between EVARand open
repair in women (3.2% vs 5.7%). In males, the 30-day mortality was 0.96%
for elective EVAR and 4.7% forelective open surgery. Following logistic
regression, female gender remains a signiﬁcant risk even when the effects
ofaneurysm size and age are considered (odds ratio 3.4, P < .01).q Full articles available online at www.jvascsurg.org
1078-5884/$ e see front matter
doi:10.1016/S1078-5884(12)00140-2Conclusions: Mortality for females undergoing elective EVAR is signiﬁ-
cantly greater than for males. It is also more hazardous. Colon ischemia,
native arterial rupture, and type 1 endoleaks are more frequent. Elective
endovascular aneurysm repair beneﬁts men more than women.
Single-center review of trends in management of abdominal aortic
aneurysms over the last decade
Sami A. Chadi, Bradley W. Rowe, Kelly N. Vogt, Teresa V. Novick, Jeremy R.
Harris, Guy DeRose, Thomas L. Forbes
Objective: The purpose of this study was to evaluate patients undergoing
elective repair of infrarenal abdominal aortic aneurysms (AAAs) and the
longitudinal trends in surgical management (open repair vs endovascular
aneurysm repair [EVAR]), factors associated with the choice of surgical
technique, and differences in the rate of in-hospital mortality at a single
large-volume Canadian center.
Method: This retrospective cohort study used data from a prospectively
collected vascular surgery database and reviewed all patients undergoing
elective repair of an infrarenal AAA over a recent 10-year period (June
2000-May 2010). Informationwas reviewed regarding surgical techniques,
patient demographics, and short-term outcomes. Subsequent analysis
included univariate statistics and multivariable logistic regression with
data presented as odds ratios (ORs) and 95% conﬁdence intervals (CIs).
Results: A total of 1942 patients underwent elective AAA repair over this
10-year study period, 1067 (54.9%) via open repair and 875 (45.1%) via
EVAR. The proportion of patients undergoing EVAR was signiﬁcantly
higher in the latter half of the study period compared to the ﬁrst half
(55.8% vs 33.9%; P < .01). Older patients (75 vs 71; P < .01) and those with
higher American Society of Anesthesiologists classiﬁcations (P < .01) were
more likely to receive endovascular repair than open repair. The overall in-
hospital mortality rate in the entire cohort was low (2.3% for EVAR and
3.9% for open repair), and after multivariable logistic regression and
adjustment for preoperative factors, in-hospital mortality was signiﬁcantly
higher in patients with open AAA repair (OR, 1.8; 95% CI, 1.04-3.13; P = .04).
Conclusion: This 10-year analysis shows a signiﬁcant shift toward an
endovascular approach in the repair of infrarenal AAAs at our Canadian
center. Similar to other jurisdictions, higher risk and older patients are
more likely to be treated with an endovascular repair resulting in a survival
advantage in these patients compared to standard open repair.
Results of carotid artery stenting with distal embolic protection with
improved systems: Protected Carotid Artery Stenting in Patients at
High Risk for Carotid Endarterectomy (PROTECT) trial
Jon S. Matsumura, William Gray, Seemant Chaturvedi, Dai Yamanouchi, Lei
Peng, Patrick Verta
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Carotid Endarterectomy (PROTECT) study was performed to evaluate the
safety and effectiveness of two devices for carotid artery stenting (CAS) in
the treatment of carotid artery stenosis in patients at high risk for carotid
endarterectomy (CEA): (1) a new embolic protection device, the
Emboshield Pro (Abbott Vascular, Abbott Park, Ill), using the periproce-
dural composite end point of 30-day death, stroke, and myocardial
infarction (DSMI), and (2) a carotid stent in conjunction with an embolic
protection device (EPD) using the DSMI periprocedural composite end
point plus ipsilateral stroke at up to 3 years for long-term evaluation.
Methods: This prospective, multicenter clinical trial enrolled 220 consec-
utive participants between November 29, 2006, and January 14, 2008,
followed by a second cohort of 102 participants between January 14 and
June 18, 2008. Enrolled participants had carotid stenosis (symptomatic
>50% or asymptomatic >80%). The ﬁrst 220 subjects underwent distal EPD
placement with a new large-diameter ﬁlter, and the second cohort of 102
underwent placement of an older EPD that is no longer manufactured. All
322 participants were to be treated with a dedicated carotid stent with
a tapered, small, closed-cell design (Xact; Abbott Vascular) and were to be
included in the long-term evaluation. Independent neurologic assessment
was performed before CAS and at 1 day, 30 days, and annually after CAS. All
primary end point events were independently adjudicated by a central
committee.
Results: The periprocedural composite end point of DSMI (95% conﬁdence
interval) in the ﬁrst 220 participants was 2.3% (0.74%, 5.22%), with
a combined death and stroke rate of 1.8% (0.50%, 4.59%) and a rate of death
and major stroke of 0.5% (0.01%, 2.51%). As of January 3, 2011, the median
follow-up for the entire 322-subject cohort for the long-term evaluation
was 2.8 years. Freedom from the periprocedural composite of DSMI plus
ipsilateral stroke thereafter was 95.4%, with an annualized ipsilateral
stroke rate of 0.4%.
Conclusions: CAS outcomes in patients at high risk for CEA have improved
from earlier carotid stent trials. With periprocedural rates of DSMI of 2.3%,
death or stroke at 1.8%, and death ormajor stroke rate of 0.5%, PROTECT has
the lowest rate of periprocedural complications among other comparable
single-arm CAS trials in patients at high risk for CEA.
Transcervical carotid stenting with ﬂow reversal is a safe technique
for high-risk patients older than 70 years
Beatriz Alvarez, Manuel Matas, Marc Ribo, Jordi Maeso, Xavier Yugueros,
Jose Alvarez-Sabin
Background: Recent evidence regarding carotid revascularization advises
against carotid angioplasty and stenting (CAS) in patients aged >70 years
with conventional risk for carotid endarterectomy (CEA). The poor
outcome of transfemoral CAS in this age group may be explained by the
anatomic characteristics of the aortic trunk and supra-aortic vessels in
elderly patients, as well as by a high prevalence of aortic arch atheroma-
tosis. Transcervical CAS with ﬂow reversal for cerebral protection avoids
these unfavorable characteristics. This study analyzed the short-term and
middle-term results of transcervical CAS with ﬂow reversal in patients
aged >70 years at high risk for CEA.
Methods: Between January 2006 and January 2011, 219 cases of >70%
carotid artery stenosis in high-risk patients aged >70 years (55.7%
asymptomatic and 44.3% symptomatic) were treated by transcervical CAS.
All patients underwent complete neurologic examination by a stroke
neurologist before and after the procedure. Primary end points were
stroke, death, or myocardial infarction (MI), technical success, and
complications at 30 days. During follow-up, we analyzed the rate of
restenosis 50% and ipsilateral stroke. Data were collected prospectively
and outcome was analyzed in all cases, including technical failures.
Results: The 30-day combined stroke/death/MI rate was 2.2% (stroke, 1.8%;
stroke/death, 2.2%; and MI, 0.45%). In symptomatic patients, stroke/death/
MI was 5.1% (stroke, 4.1%; stroke/death, 5.1%). None of the asymptomatic
patients suffered stroke, MI, or death postoperatively. Technical success
was 96.3% (four inability to cross lesion, two major common carotid
dissections, one failed preangioplasty, one stent thrombosis). One cervical
hematoma required surgical drainage. At follow-up (18.8  16.9 months),
cumulative (standard error) incidence of >70% restenosis was 3% (1%) at 1year and 8% (3%) at 2 and 3 years. Only one patient experienced ipsilateral
stroke during follow-up. Overall survival (standard error) was 94% (2%) at 1
year and 90% (3%) at 2 and 3 years.
Conclusions: In our experience, transcervical CAS with ﬂow reversal is
a safe technique for treating carotid stenosis in patients aged >70 years.
We believe that avoiding the aortic arch and tortuous supra-aortic vessels
is responsible for the favorable results in this study.
Optimal conduit choice in the absence of single-segment great
saphenous vein for below-knee popliteal bypass
James T. McPhee, Neal R. Barshes, C. Keith Ozaki, Louis L. Nguyen, Michael
Belkin
Background: Single-segment great saphenous vein (SSGSV) remains the
conduit of choice for femoral to below-knee popliteal (FeBK) surgical
revascularization. The purpose of this study was to determine the optimal
conduit in patients with inadequate SSGSV.
Methods: This was a retrospective review of a prospectively maintained
vascular registry. Patients underwent FeBK bypass with alternative vein
(AV; arm vein, spliced GSV, or composite vein) or prosthetic conduit (PC).
Results: From January 1995 to June 2010, 83 patients had unusable SSGSV
for FeBK popliteal reconstruction. Thirty-three patients had an AV conduit
and 50 had PC. The AV group was a lower median age than the PC group
(69 vs 75 years). The two groups were otherwise similar in comorbid
conditions of diabetes mellitus (57.6% vs 58.0%; P > .99), smoking (15.2% vs
32.0%; P = .12), and hemodialysis (3% vs 12%; P = .23). The groups were
similar in baseline characteristics such as limb salvage as indication (93.9%
vs 86.0%; P = .31), mean runoff score (5.2 vs 4.6; P = .39), and prior ipsi-
lateral bypass attempts (18.2% vs 18.0%; P > .99). The AV and PC groups
were also similar in 30-day mortality (6.1% vs 4.0%; P > .99) and wound
infection rates (6.1% vs 6.0%; P > .99). PC patients were more likely to be
discharged on Coumadin (Bristol-Myers Squibb, Princeton, NJ) than AV
patients (62.0% vs 27.3%; P = .002). Seventeen of the 50 PC patients (34%)
had a distal anastomotic vein cuff. A log-rank test comparison of 5-year
outcomes for the AV and PC groups found no signiﬁcant difference in
primary patency (55.3%  9.9% vs 51.9%  10.8%; P = .82), assisted primary
patency (68.8%  9.6% vs 54.0%  11.0%; P = .45), secondary patency (68.4%
 9.6% vs 63.7%  10.4% for PC; P = .82), or limb salvage rates (96.2%  3.8%
vs 81.1%  8.1%; P = .19). Multivariable analysis demonstrated no associa-
tion between conduit type and loss of patency or limb. The factors most
predictive of primary patency loss were limb salvage as the indication for
surgery (hazard ratio [HR], 4.23; 95% conﬁdence interval [CI], 1.65-10.9; P =
.003) and current hemodialysis (HR, 3.51; 95% CI, 1.08-11.4; P = .037). The
most predictive factor of limb loss was current hemodialysis (HR, 7.02; 95%
CI, 1.13-43.4; P = .036).
Conclusions: For patients with inadequate SSGSV, PCs, with varying
degrees of medical and surgical adjuncts, appear comparable to AV sources
in graft patency for below-knee popliteal bypass targets. This observation
is tempered by the small cohort sample size of this single-institutional
analysis. Critical limb ischemia as the operative indication and current
hemodialysis predict impaired patency, and hemodialysis is associated
with limb loss.
Placement of a retrievable inferior vena cava ﬁlter for deep venous
thrombosis in term pregnancy
Yang Liu, Yan Sun, Shiyi Zhang, Xing Jin
Objective: Venous thromboembolism is a signiﬁcant cause of morbidity
and death in pregnant women. Retrievable vena cava ﬁlters were placed
right before labor as prophylaxis for peripartum pulmonary embolism. We
reviewed the experience of caval ﬁlter placement and retrieval in term
pregnancy in this study.
Methods:We reviewed 15 patients with deep venous thrombosis (DVT) of
the lower extremity who underwent OptEase (Cordis Corp, New Bruns-
wick, NJ) retrievable vena cava ﬁlter placement. DVT was diagnosed by
clinical symptoms and Doppler ultrasound imaging. Subcutaneous low-
molecular-weight heparin was eased 12 hours before cesarean delivery
and restarted 12 hours after delivery. The caval ﬁlters were placed
Abstracts / European Journal of Vascular and Endovascular Surgery 43 (2012) 488e490490suprarenally from the jugular approach and retrieved from the femoral
approach.
Results: The ﬁlters were successfully placed in all patients on the day of
cesarean delivery. No placement-related complications occurred. The caval
ﬁlter was left in situ as a permanent device in one patient because the
captured thrombus within the ﬁlter was not eliminated after the throm-
bolytic therapy. Filters in other 14 patients were retrieved successfully,
without difﬁculty, including in one patient after complete lysis of captured
thrombus by the thrombolytic therapy. Oral warfarin therapy was rec-
ommended for at least 3 months after hospital discharge, and for at least 6
months in the patient with a caval ﬁlter left in situ. All patients were
examined by Doppler ultrasound imaging during the follow-up. None
presented with symptomatic pulmonary embolism or ﬁlter-related
complications.
Conclusions: OptEase retrievable vena cava ﬁlter placement and retrieval
in term pregnant patients with extensive DVT of the lower extremities is
safe, effective, and feasible. The results in our study may justify prophy-
lactic ﬁlter placement use right before labor.
Endovascular treatment of hemodialysis access pseudoaneurysms
Aamir S. Shah, Jaime Valdes, Kristofer M. Charlton-Ouw, Zhongxue Chen,
Sheila M. Coogan, Hammad M. Amer, Anthony L. Estrera, Hazim J. Saﬁ, Ali
Azizzadeh
Objectives: Pseudoaneurysm (PSA) formation is a complication of hemo-
dialysis access. Open repair requires PSA resection, interposition graft
placement, and insertion of a catheter as a bridge. Endovascular stent graft
repair is an alternative that permits immediate use of the access site. The
objective of this study was to determine the efﬁcacy of stent grafts for
repair of arteriovenous ﬁstula and arteriovenous graft PSA.
Methods: A retrospective review of medical records from October 2007 to
March 2011 revealed 24 patients with a PSAwho underwent endovascular
repair using a stent graft. Indications for repair included PSA with symp-
toms (n = 11), PSAwith skin erosion (n = 8), PSAwith failed hemodialysis (n
= 3), and PSA after balloon angioplasty of a stenosis (n = 2). Outcome
measures were technical success, 30-day and 180-day patency, secondary
interventions, and complications. All the statistical analyses were con-
ducted by using software SAS 9.1 (SAS, SAS Institute, Gary, NC).
Results: Twenty-seven self expanding stent grafts (Viabahn, W. L. Gore, n =
25; Fluency, Bard, n = 2) were used to treat hemodialysis access (arterio-
venous graft, n = 13; arteriovenous ﬁstula, n = 11) PSA in 24 patients (16
females; mean age, 55.7 years; mean body mass index, 28.4; mean PSA
diameter, 19.5 mm). Comorbidities included hypertension (n = 22; 91.7%),
diabetesmellitus (n = 8; 33.3%), and coronary artery disease (n = 4; 16.67%).
The median time from access creation to repair was 455 days. The tech-
nical success rate was 100%. Balloon angioplasty of an outﬂow stenosis was
performed in 56% of stent grafts. The 30- and 180-day patency rate was
100% and 69.2%, respectively. Three secondary interventions were per-
formed for treatment of unrelated stenosis. Treatment failure occurred inﬁve (18.5%) stent grafts due to infection (n = 3) and thrombosis (n = 2).
Treatment of PSA with skin erosion was associated with failure due to
infection (odds ratio, 5.0; 95% conﬁdence interval, .38, 66.01). The
remaining 22 (81.5%) stent grafts remain patent. The mean follow-up time
was 268.9 days (median 97.5).
Conclusions: Endovascular therapy is an effective and durable treatment
option for patients with dialysis access PSAs. This technique permits
immediate use of the hemodialysis access site as well as identiﬁcation and
treatment of associated stenosis. It may be considered as an alternative to
open repair in patients who are anatomically suitable candidates.
Mesenteric artery complications during angioplasty and stent
placement for atherosclerotic chronic mesenteric ischemia
Gustavo S. Oderich, Tiziano Tallarita, Peter Gloviczki, Audra A. Duncan,
Manju Kalra, Sanjay Misra, Stephen Cha, Thomas C. Bower
Objective: The purpose of this study was to describe the incidence,
management, and outcomes of mesenteric artery complications (MACs)
during angioplasty and stent placement (MAS) for chronic mesenteric
ischemia (CMI).
Methods: We retrospectively reviewed the clinical data of 156 patients
treated with 173 MAS for CMI (1998-2010). MACs were deﬁned as proce-
dure-related mesenteric artery dissection, stent dislodgement, emboliza-
tion, thrombosis, or perforation. End points were procedure-related
morbidity and death.
Results: There were 113 women and 43 men (mean age, 73  14 years).
Eleven patients (7%) developed 14 MACs, including distal mesenteric
embolization in six, branch perforation in three, dissection in two, stent
dislodgment in two, and stent thrombosis in one. Five patients required
adjunctive endovascular procedures, including in two patients each,
catheter-directed thrombolysis or aspiration, retrieval of dislodged stents,
and placement of additional stents for dissection. Five patients (45%)
required conversion to open repair: two required evacuation of mesenteric
hematoma, two required mesenteric revascularization, and one required
bowel resection. There were four early deaths (2.5%) due to mesenteric
embolization or myocardial infarction in two patients each. Patients with
MACs had higher rates of mortality (18% vs 1.5%) and morbidity (64% vs
19%; P<.05) and a longer hospital length of stay (6.3 4.2 vs 1.6 1.2 days)
than those without MACs. Periprocedural use of antiplatelet therapy was
associated with lower risk of distal embolization or vessel thrombosis
(odds ratio, 0.2; 95% conﬁdence interval, 0.06-0.90). Patients treated by
a large-proﬁle system had a trend toward more MACs (odds ratio, 1.8; 95%
conﬁdence interval, 0.7-26.5; P = .07).
Conclusions: MACs occurred in 7% of patients who underwent MAS for
CMI and resulted in higher mortality, morbidity, and longer hospital length
of stay. Use of antiplatelet therapy reduced the risk of distal embolization
or vessel thrombosis. There was a trend toward more MACs in patients
who underwent interventions performed with a large-proﬁle system.
